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A B S T R A C T   
Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy 
(MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy. 
Tirofiban is a glycoprotein IIb/IIIa used throughout the world now more commonly used during MT. We report 
the analysis of all AIS patients treated with Eptifibatide + MT vs. Tirofiban + MT. 
Methods: Using a prospectively collected endovascular database at a CSC between 2013 and 2019, workflow, and 
outcomes were recorded. Patients are given Tirofiban, and patients given Eptifibatide were analyzed to obtain 
baseline demographics, modified Ranking Scale (mRS) at discharge, and 90 days follow up, pre and post 
thrombolysis in cerebral infarction (TICI), mortality rate, and hemorrhage rates. 
Results: A total of 571 MT patients were treated: of those, 89 patients (average age 69.25 ± 14.21, 25.84% fe-
male) with underlying intracranial atherosclerosis were treated with a GpIIb/IIIa inhibitor. Analysis of 40.45% 
(36/89) patients treated with Tirofiban + MT and 59.55% (53/89) patients with Eptifibatide + MT was per-
formed. There was no statistically significant difference in NIHSS upon admission (p = .441). Four patients 
(11.11%) in the Tirofiban + MT cohort had symptomatic hemorrhage versus four patients (7.55%) in the 
Eptifibatide + MT cohort (p = .564). There was no significant difference in mortality (p = .573) or final 
recanalization (p = .678) between the two cohorts. 
Conclusion: Tirofiban use in MT does not increase the risk of symptomatic hemorrhages or mortality compared to 
Eptifibatide use in MT with acute stenting. Large prospective studies are warranted to confirm the safety/efficacy 
of Tirofiban in acute ischemic stroke patients treated with mechanical thrombectomy and acute stenting.   
1. Introduction 
Glycoprotein IIB/IIA inhibitor use during mechanical thrombectomy 
is becoming an established practice of treating acute ischemic stroke 
patients with mechanical thrombectomy (MT), pushing for assistance 
from various medications. Glycoprotein IIb-IIIa inhibitors (Eptifibatide, 
Tirofiban, Abciximab) are used globally during the treatment of acute 
stroke patients with underlying intracranial atherosclerosis requiring 
acute angioplasty and or stenting; Recently, Tirofiban is substituting 
Eptifibatide use due to decreased cost [1]. Moreover, tissue plasminogen 
activator (tPA) in conjunction with glycoprotein inhibitors enhances 
clot’s dissolution [2]. Likewise, tPA, in addition to Tirofiban, improves 
the recanalization rate of a cerebral artery, while the increased risk of 
hemorrhage has not been documented [3,4]. 
Previous research has shown that Eptifibatide is the norm of treat-
ment for underlying intracranial atherosclerosis; however, the recent 
switch to Tirofiban to treat underlying intracranial atherosclerosis is 
raising concerns of safety and effectiveness. Each GpIIb/IIIa inhibitor 
prevents the aggregation of platelets through varying processes. For 
instance, Eptifibatide prevents the ability to bind to the activated 
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platelet while Tirofiban inhibits the last common step of thrombi for-
mation [3–5]. Another difference is that Eptifibatide has less receptor 
affinity than Tirofiban, resulting in dissociation from the receptor faster 
[3–5]. Both inhibitors have been published on in acute stroke, Chahal 
et al. demonstrated that Eptifibatide utilized with MT improves patient 
outcome and safety by suppressing inflammation and prevention of 
rethrombosis [4,6,7]. While Yu T displayed that Tirofiban facilitates 
reperfusion of distal vessel while improving patient outcome [3,8,9]. We 
aim to report on a small cohort of acute ischemic stroke patients and 
compare those treated with Eptifibatide + MT to those treated with 
Tirofiban + MT to distinguish differences and similarities in patient 
outcomes when treating underlying intracranial atherosclerosis with 
GpIIb/IIIa inhibitors. 
2. Methods 
A retrospective study was conducted including AIS patients with 
underlying intracranial atherosclerosis between August of 2013 to 
January 2019 and from August 2017 to January 2019 across two-stroke 
centers. The two institutions compiled a prospectively maintained 
database. One of the two-stroke centers used Eptifibatide from May 
2013 to July 2017 and subsequently switched to Tirofiban in August 
2018. One of the stroke centers used Tirofiban for very few stroke cases 
and used Cangrelor for other cases. Eptifibatide was not used at one of 
the stroke centers. The process for data collection was approved/ 
reviewed at each respective institution. 
2.1. Interventional and post procedural parameters 
Mechanical thrombectomy cases were treated with a stent retriever 
and distal catheter aspiration using the Solumbra technique. The 
regimen of Tirofiban and Eptifibatide used consisted of intravenous 
administration based on the weight of the patient. The Tirofiban bolus 
was administered at 12mcg/kg over 30 min. For a detailed adminis-
tration of intravenous Tirofiban, refer to Table 1. Following this 
regimen, a maintenance drip for 6–12 h at 0.1 mcg/kg/min and a bolus 
of 300–600 mg Plavix and 325 mg of aspirin were given. 
Similarly, to Tirofiban administration, eptifibatide was administered 
2mcg/kg/min bolus intravenously over 30 min, followed by 0.5mcg/kg/ 
min infusion for 6–12 h after 300–600 mg Plavix bolus and 325 mg of 
aspirin. If the patient presents with a change, a noncontrast CT of the 
head was performed. If an intracranial hemorrhage was discovered, the 
glycoprotein IIIB/IIIA was discontinued, and neurosurgery consulted. 
2.2. Data collected 
We compiled patient demographic data (i.e., gender, race/ethnicity, 
age) and co-morbid conditions (i.e., hypertension, diabetes mellitus, 
atrial fibrillation, cigarette smoking, atrial fibrillation, congestive heart 
failure, and coronary artery disease) from the prospectively maintained 
database. Modified Rankin Scale (mRS) score at discharge and NIHSS 
score upon admission were obtained from the prospectively maintained 
database. A collection of pre-thrombolysis in cerebral infarction (TICI) 
and post TICI values were collected as well as symptomatic intracerebral 
hemorrhage (SICH) and mortality rates. SICH is defined as an ICH on a 
24-hour CT scan and a decrease in NIHSS score of 4 or more. Additional 
data regarding the site of occlusion, recanalization occurrence, and 
mechanical thrombectomy specifics. 
2.3. Statistical analysis 
We conducted an analysis consisting of AIS patients receiving me-
chanical thrombectomy treated with either angioplasty alone or angio-
plasty with a stent or neither in addition to either Eptifibatide or 
Tirofiban. We performed univariate analyses to identify differences in 
baseline characteristics, IV tPA use, and outcomes of both cohorts. The t- 
test was used for continuous variables, and the chi-square test was used 
for categorical variables. Outcomes analyzed included symptomatic 
hemorrhage rates, mortality rates at discharge, NIHSS score upon 
admission, mRS 0–2 scores at discharge, and TICI score 2b-3. Logistic 
regression analyses were performed to determine the correlation be-
tween MT + Tirofiban/MT + Eptifibatide and (1) symptomatic hemor-
rhage, (2) mortality rate at discharge, (3) good outcome at discharge 
(0–2), (4) good TICI score (2b-3). All variables that were determined to 
be significant in the univariate analysis were added to the logistic 
regression model. In the model analysis, the variables that were included 
are atrial fibrillation (AF) rate (categorical), IV tPA use (categorical), 
and NIHSS score upon admission (continuous). Statistical analysis was 
performed using IBM SPSS statistical software. 
3. Results 
A total of 571 mechanical thrombectomy patients from May 2013 to 
January 2019 composed of 86.16% (492/571) and 13.84% (79/571) 
from 2 CSC centers from August 2017 to January 2019 were initially 
gathered. A total of 89 patients received a GpIIb/IIIa inhibitor and MT 
treated with either angioplasty, angioplasty and stenting, or stenting 
during the study period (average age 69.25 ± 14.21, 25.84% female) 
across two-stroke centers. Only patients with mechanical thrombectomy 
and either Eptifibatide or Tirofiban were included. From the dataset, 
approximately 75% and 83% of individuals from Eptifibatide and Tir-
ofiban respectively underwent mechanical thrombectomy with a stent 
and angioplasty. Further specifics on stenting and angioplasty alone are 
summarized in Table 2. Site of Occlusion in which most of the 
Table 1 
Tirofiban Protocol/Regimen.  
INTRAVENOUS (250 mL bag) 
Weight 
(kg) 
Bolus 12 mcg/kg over 30 
min 






30–37 8 16 4 
38–45 10 20 5 
46–54 12 24 6 
55–62 14 28 7 
63–70 16 32 8 
71–79 18 36 9 
80–87 20 40 10 
88–95 22 44 11 
96–104 24 48 12 
105–112 26 52 13 
113–120 28 56 14 
121–128 30 60 15 
129–137 32 64 16 
138–145 34 68 17 
146–153 36 72 18  
Table 2 
Interventional Procedure.   
Eptifibatide + MT (N = 53) Tirofiban + MT (N = 36) 
Angioplasty or Stenting 
Angioplasty Alone 6 5 
Stenting Alone 4 1 
Angioplasty + Stenting 40 30 
Occlusion Site   
Middle Cerebral Artery 40 23 
Internal Carotid Artery 8 10 




Common Carotid Artery 0 1 
Basilar Artery 1 1 
Vertebral Artery 0 1  
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procedures took place for both cohorts is the middle cerebral artery. Out 
of the 89 patients, 40.45% (36/89) were treated with Tirofiban + MT 
(average age 69.25 ± 14.18, 27.78% female) and 59.55% (53/89) were 
treated with Eptifibatide + MT (average age 69.25 ± 14.36, 24.53%). 
Baseline demographics, risk factors, and outcomes are summarized in 
Table 3. 
The IV tPA use did show a statistical difference between the two 
groups (p = .01). Reperfusion was successful (TICI 2b/3) in 94.44% of 
Tirofiban + MT cases compared to 92.16% of Eptifibatide + MT cases (p 
= .678). NIHSS scale upon admission for Eptifibatide + MT patients 
(average NIHSS score 14.55 ± 8.599) compared to Tirofiban + MT 
(average NIHSS score 13.08 ± 9.057) (p = .441). Four patients (11.11%) 
in the Tirofiban + MT group had symptomatic hemorrhage versus four 
patients (7.55%) in the Eptifibatide + MT (p = .564). The mortality rate 
at discharge did not show a statistical difference between the two groups 
(p = .573). Good clinical outcome at discharge (mRS ≤ 2) was achieved 
in 35.85% of Eptifibatide + MT patients and 30.56% of Tirofiban + MT 
patients (p = .604). Things to consider on the rate of good outcomes at 
discharge is that we routinely treat patients with mRS of 3 at baseline 
with LVO and significant change in functional ability, we also were 
treating more patients in the later time windows during and after the 
DAWN and DEFUSE 3 trials. 
Results of the univariate analysis for baseline characteristics, IV tPA 
use, and clinical outcomes are summarized in Table 1. IV tPA use 
demonstrated a statistically significant difference between Eptifibatide 
+ MT and Tirofiban + MT groups. All other variables did not show a 
strong trend towards a significant difference (P > .05) and, therefore, 
were not included in the multivariate analysis. 
Subsequently, a multivariate analysis was conducted with statisti-
cally significant variables summarized in Table 4. The odds of symp-
tomatic hemorrhage (OR 0.729, 95% CI 0.155–3.440), the mortality rate 
at discharge (OR 1.288, 95% CI 0.406–4.088), the good outcome at 
discharge (OR 1.364, 95% CI 0.490–3.798), and good TICI score (OR 
0.700, 95% CI 0.107–4.564) showed no statistically significant differ-
ence between the two groups. 
4. Discussion 
The analysis of acute ischemic stroke patients treated with me-
chanical thrombectomy and acute stenting while treated with Tirofiban 
showed no significant difference compared to those patients treated 
with Eptifibatide. There was no difference in symptomatic hemorrhage 
rates, mortality at discharge, discharge mRS scores, and TICI scores 
between the two groups. The multivariate analysis respectively for 
Eptifibatide + MT and Tirofiban + MT cohorts: symptomatic hemor-
rhage rates 7.55% and 11.11% (p = .564), mortality rates 24.53% and 
19.44% (p = .573), rate of good clinical outcome (mRS dc 0–2) 35.85% 
and 30.56% (p = .604), and TICI score 2b-3 rates are 92.16% and 
94.44% (p = .678). Tirofiban and MT in patients with underlying 
intracranial atherosclerosis show no difference in the variables studied 
when compared to Eptifibatide. 
Our study shows a similarly favorable outcome of mechanical 
thrombectomy and acute stenting following IV infusion of tirofiban with 
similar sICH rates, mortality rates, and favorable outcome rates with the 
Eptifibatide cohort a well-established glycoprotein IIB/IIIA inhibitor. 
Although there has been data on Tirofiban application in coronary ar-
tery disease and intracranial aneurysms, there has been a lack of evi-
dence in the safety and efficacy of Tirofiban in conjunction with 
mechanical thrombectomy of intracranial disease. Eptifibatide has been 
used in the clinical treatment setting longer than Tirofiban, but recently 
there has been a push for Tirofiban’s use in conjunction with mechanical 
thrombectomy. Our study aids in the evidence of pushing for Tirofiban 
in conjunction with mechanical thrombectomy when acute stenting is 
needed. 
Placement of stents require antiplatelet therapy, which can poten-
tially increase the risk of intracranial hemorrhages. In our study, Tir-
ofiban and Eptifibatide groups exhibited an 11.11% and 7.55% 
intracerebral hemorrhage rates post-intervention which are lower than 
intracerebral hemorrhage rates of 18% in a cohort of mechanical 
thrombectomy with tandem lesions [10]. Bleeding complications in our 
series did not show higher hemorrhagic rates These results are compa-
rable with data of retrospective studies of 141 and 19 patients treated 
with endovascular therapy involving stenting and Tirofiban, which 
showed hemorrhagic rates of 15.7% and 8.8% [11,12]. The rate of 
Tirofiban + MT is 11.11% was relatively similar to a comparative study 
of AIS patients who underwent mechanical without Tirofiban of 10.2%, 
[13] but also similar to hemorrhage rate of mechanical thrombectomy 
with Tirofiban of 10.6% [13]. However, in the study by Kellert et al., 
they reported higher rates of symptomatic intracerebral hemorrhage in 
stroke patients receiving intravenous tirofiban [14]. Several factors can 
account for the high sICH such as patients had a higher NIHSS upon 
admission of roughly 18, which is higher than Tirofiban + MT patients 
in our study was 13, and more than ten different devices were used in the 
mechanical thrombectomy cases analyzed, which could lead to the high 
number of sICH. Despite these results, our study shows that IV 
Table 3 
Univariate analysis evaluating baseline variables, procedural characteristics and 
outcomes.  
Overall Number (%) Eptifibatide + MT 
(N = 53) 
Tirofiban + MT 
(N = 36) 
P 
value 
Age (mean ± SD) 69.25 ± 14.36 69.25 ± 14.18  0.406 
Gender    0.620 
Men 40 (75.47) 26 (72.22)  
Women 13 (24.53) 10 (27.78)  
Race/ethnicity    0.214 
Hispanic 39 (73.58) 22 (61.11)  
White 14 (26.42) 14 (38.89)  
Co-morbid conditions    
Hypertension 47 (88.68) 28 (77.77)  0.165 
Diabetes Mellitus 26 (49.06) 14 (38.89)  0.344 
Atrial fibrillation 15 (28.3) 3 (8.33)  0.021 
Cigarette smoking 11 (20.75) 5 (13.88)  0.407 
Coronary artery disease 10 (18.68) 7 (19.44)  0.949 
Congestive heart failure 6 (11.32) 5 (13.89)  0.719 
In-hospital complication    
Intracerebral hemorrhage 
(symptomatic hemorrhage) 
4 (7.55) 4 (11.11)  0.564 
Thrombolysis in cerebral 
infarction    
Good (post TICI score 2b-3) 47 (92.16) 34 (94.44)  0.678 
Outcome (mean ± SD) 3.358 ± 2.058 3.611 ± 1.793  0.5507 
Good (mRS discharge score 
0–2) 
19 (35.85) 11 (30.56)  0.604 
Mortality at Discharge 13 (24.53) 7 (19.44)  0.573 
IV tPA use 20 (37.74) 5 (13.89)  0.01 
NIHSS upon admission 14.55 ± 8.599 13.08 ± 9.057  0.441  
Table 4 
Multivariate analysis evaluating effect of Tirofiban on outcomes of acute 
ischemic stroke patients who underwent endovascular treatment.  
Outcomes Unadjusted Adjusted for Afib, IV tPA 
and NIHSS  
OR (95% CI) P 
value 
















Good outcome at 
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administration of Tirofiban is as effective and safe as a prevalently used 
glycoprotein IIB/IIA inhibitor (Eptifibatide). 
The average NIHSS mean for Eptifibatide and Tirofiban cohort 
respectively were 14.55 ± 8.599 and 13.08 ± 9.057, which are better 
than the tandem cohort consisting of 17.6 ± 5.0 [10]. Furthermore, our 
analysis had TICI scores 2b-3 rates better than the tandem lesion group 
TICI scores. Cureus et al. reported a 100% TICI score of 2b-3 in a cohort 
size of 6 administered with glycoprotein IIB/IIIa inhibitor for large 
vessel occlusion [15]. Favorable post-TICI score was significantly higher 
than patients without an antiplatelet therapy in large multicenter 
retrospective analysis [16]. Additionally, the rate of a good outcome was 
measured at discharge and not followed up at 90 days since approxi-
mately 40% of patients did not come back for follow and, therefore, 
unable to provide data regarding post-discharge. 
The negligible differences in safety and effectiveness could be a 
result of contrary chemical structures. For example, Tirofiban is half the 
molecular weight of Eptifibatide [3–5]. Based on a study regarding 
glycoproteins chemical structures, Eptifibatide is a synthetic cyclic 
heptapeptide with cysteine bridges, while Tirofiban is a small, non-
peptide, tyrosine-like peptidomimetic [3–5]. As well as, Tirofiban has a 
higher specificity and affinity for glycoprotein IIb and IIIa receptors 
allowing it not to dissociate as fast as Eptifibatide [3–5]. Despite these 
differences, both glycoproteins have very similar safety and effective-
ness when treating underlying intracranial atherosclerosis. Another 
reason Tirofiban can be more effective is that it “dissociates from the 
receptor at a half-life of 11 s,” which is faster than Eptifibatide: 
furthermore: Tirofiban has a shorter half-life allowing its antiplatelet 
effect to seize as soon as infusion halts [3,4,17]. 
Specific limitations of our study must be taken into consideration. 
First, the study was conducted retrospectively and contained non- 
standardized treatment. Second, the small sample size is a limitation. 
Furthermore, interventional teams have gained experience using gly-
coproteins inhibitors, which affected surgeries in the earlier period. 
Third, between 2016 and 2017, there was an inclusion of wake-up 
strokes due to the DAWN trial, which affected the data during that 
time frame. Lastly, our data, compared to many other studies did not 
have any inclusion or exclusion criteria. However, these limitations do 
not significantly influence the principal results. 
5. Conclusion 
In conclusion, mechanical thrombectomy and acute stenting with 
Tirofiban does not intensify the risk of hemorrhage or mortality 
compared to Eptifibatide. There was no statistically significant differ-
ence in symptomatic hemorrhage, mortality rates, and discharge out-
comes demonstrating the equivalent effectiveness/safety. Tirofiban 
provides an alternative agent in conjunction with mechanical throm-
bectomy and acute stenting. More extensive studies are warranted to 
prove the safety and efficacy of Tirofiban compared to Eptifibatide in 
acute ischemic stroke patients treated with mechanical thrombectomy 
and acute stenting. 
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